Can a consumer DNA test interpret CYP1A2 reliably?

Consumer DNA tests (e.g., MyBody-X) can genotype CYP1A2 (e.g., rs762551) with high technical accuracy (>99%). However, the interpretation as 'fast' or 'slow' caffeine metabolizer is only moderately supported by evidence. Enzyme activity is heavily modulated by lifestyle: smoking induces CYP1A2, oral contraceptives inhibit it, and diet (grapefruit, cruciferous vegetables) and medications also alter activity. Clinical utility for health recommendations (e.g., caffeine intake and cardiovascular risk) remains debated; prospective studies show inconsistent associations. The test provides a genetic tendency, not a diagnosis or reliable action plan. Evidence is based on association studies (human-moderate), not RCTs. Consumers should be cautious about making drastic changes to caffeine consumption based solely on this result. Caveat: ethnic differences (e.g., higher frequency of slow metabolizers in Asian populations) are often underreported.